Interaction #22: 3C-like protease-Atazanavir
Computational
positive
Related publications
Title
Author
Type
Discovering drugs to treat coronavirus disease 2019 (COVID-19). Liying Dong, Shasha Hu, Jianjun Gao
Research
In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins Irene Maffucci, Alessandro Contini
Research
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction de Bo Ram Beck, Bonggun Shin, Yoonjung Choi, Sungsoo Park, Keunsoo Kang
Research
Supercomputer-aided Drug Repositioning at Scale: Virtual Screening for SARS-CoV-2 Protease Inhibitor Sangjae Seo, Jung Woo Park, Dosik An, Junwon Yoon, Hyojung Paik, Soonwook Hwang
Research
Molecular Investigation of SARS–CoV-2 Proteins and Their Interactions with Antiviral Drugs Calligari P, Bobone S, Ricci G, Bocedi A
Research
Antiretroviral Drug Activity and Potential for Pre-Exposure Prophylaxis Against COVID-19 and HIV Infection Dennis C. Copertino Jr., Bruno Lima, Rodrigo Duarte, Timothy Wilkin, Roy Gulick, Miguel de Mulder Rougvie, Douglas Nixon
Research
Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs Zhe Li, Xin Li, Yi-You Huang, Yaoxing Wu, Runduo Liua, Lingli Zhou, Yuxi Lin, Deyan Wu, Lei Zhang, Hao Liu, Ximing Xu, Kunqian Yu, Yuxia Zhang, Jun Cui, Chang-Guo Zhan, Xin Wang, Hai-Bin Luo
Research
A Study of Potential SARS-CoV-2 Antiviral Drugs and Preliminary Research of Their Molecular Mechanism, Based on Anti-SARS-CoV Drug Screening and Molecular Dynamics Simulation Xiaomeng Zhao, Ruixia Liu, Zhi Miao, Nan Ye, Wenyu Lu
Research
An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease. Nemanja Djokovic, Dusan Ruzic, Teodora Djikic, Sandra Cvijic, Jelisaveta Ignjatovic, Svetlana Ibric, Katarina Baralic, Aleksandra Buha Djordjevic, Marijana Curcic, Danijela Djukic-Cosic, Katarina Nikolic,
Research
Target
Target affiliation
Drug
Type
Result
Target
Target affiliation
Drug
Type
Result
Name
Synonyms
Genes
Origin
Name
Synonyms
Genes
Origin
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Title
Authors
DOI
Source
Article type
Date
Title
Authors
DOI
Source
Article type
Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID.
It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial
